The Expression, Function and Targeting of Haem Oxygenase-1 in Cancer

ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)

Volume 17, 9 Issues, 2017

Download PDF Flyer

Current Cancer Drug Targets

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 68th of 213 in Oncology

Submit Abstracts Online Submit Manuscripts Online

Ruiwen Zhang
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.707
5 - Year: 3.446

The Expression, Function and Targeting of Haem Oxygenase-1 in Cancer

Current Cancer Drug Targets, 14(4): 337-347.

Author(s): Mads Duus Hjortso and Mads Hald Andersen.

Affiliation: Center for Cancer Immune Therapy (CCIT), Department of Hematology, 54P4, Copenhagen University Hospital, Herlev, Denmark.


Haem oxygenase-1 (HO-1) catalyses the rate-limiting step in haem degradation. All three metabolites resulting from haem degradation (carbon monoxide (CO), biliverdin and free iron) have anti-inflammatory and anti-apoptotic properties. HO-1 is a stress-inducible enzyme found extensively expressed in a vast variety of both human and murine cancers, where it serves as an essential survival molecule by modulating expression of molecules regulating apoptosis and stimulating angiogenesis. In addition, HO-1 contributes in a critical manner to inhibition or termination of inflammation. Consequently, several anticancer strategies aim at targeting HO-1. The inhibition of HO-1 may cause tumour cells to become more sensitive to chemotherapy and radiation therapy. The water-soluble forms of the HO-1 inhibitor Zinc protoporphyrin (ZnPP) have seemed promising in different in-vivo models, in which it has induced growth arrest in tumour cells with few, if any, side effects. Studies have suggested that HO-1 may also function to disrupt the tumour metastasising process, since the expression of the metalloprotease MMP9 is inversely correlated with HO-1 expression.

Additionally, HO-1 has anti-inflammatory functions which play a very important role in the negative regulation of the immune system. Immunological targeting of HO-1 might represent an interesting approach, as epitopes derived from HO- 1 have been found exclusively on tumour tissue. Natural HO-1-specific T-cell responses have been identified in cancer patients. Hence, recently HO-1-specific, CD8+ regulatory T cells were described in cancer patients, which in concert with HO-1 expression might be responsible for a highly immunosuppressive tumour microenvironment.

Here, we summarise current knowledge of the role of HO-1 in cancer, report the different results of the targeting of HO-1 in preclinical and clinical settings, and discuss future opportunities.


Cancer, haem oxygenase-1, regulatory T cells, tumour immunology, zinc protoporphyrin.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 14
Issue Number: 4
First Page: 337
Last Page: 347
Page Count: 11
DOI: 10.2174/1568009614666140320111306
Price: $58
Global Biotechnology Congress 2017Drug Discovery and Therapy World Congress 2017Orphan Drugs and Rare Diseases Europe 2017

Related Journals

Related eBooks

Webmaster Contact: Copyright © 2017 Bentham Science